Table 2 ROC curves of HPT+/AAAD+ patients and HPT+/AAAD− individuals in blinded trail set.
Risk score | AUC (95% CI) | P-value | Cutoff point | Sensitivity | Specificity | PV+ | PV− |
|---|---|---|---|---|---|---|---|
4-miR panel | 0.973 (0.918–1.000) | <0.001 | 36.89% | 93.33% | 86.67% | 87.50% | 92.86% |
miR-25 | 0.987 (0.937–1.000) | <0.001 | 1.353 | 86.67% | 93.33% | 92.86% | 87.50% |
miR-29a | 0.951(0.856–1.000) | <0.001 | 1.354 | 93.33% | 93.33% | 93.33% | 93.33% |
miR-155 | 0.764 (0.576–0.952) | 0.014 | 1.457 | 73.33% | 86.67% | 84.62% | 76.47% |
miR-26b | 0.822(0.668–0.977) | 0.003 | 0.500 | 73.33% | 86.67% | 84.62% | 76.47% |